NCT04475523View on ClinicalTrials.gov

Phase 1 Study of CI-8993 Anti-VISTA Antibody in Patients With Advanced Solid Tumor Malignancies

PHASE1CompletedINTERVENTIONAL
Enrollment

26

Participants

Timeline

Start Date

September 22, 2020

Primary Completion Date

May 19, 2023

Study Completion Date

May 19, 2023

Conditions
Solid Tumor
Interventions
DRUG

CI-8993

CI-8993 is a fully human immunoglobulin (Ig) G1κ monoclonal antibody (mAb) against the VISTA ligand

Trial Locations (6)

3199

Peninsula & South Eastern Haematology and Oncology Group, Frankston

10065

Memorial Sloan Kettering Cancer Center, New York

14263

Roswell Park Cancer Institute, Buffalo

37203

The Sarah Cannon Research Institute/Tennessee Oncology, Nashville

77030

The University of Texas MD Anderson Cancer Center, Houston

03756

Dartmouth-Hitchcock Medical Center, Lebanon

All Listed Sponsors
lead

Curis, Inc.

INDUSTRY

NCT04475523 - Phase 1 Study of CI-8993 Anti-VISTA Antibody in Patients With Advanced Solid Tumor Malignancies | Biotech Hunter | Biotech Hunter